Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women.

Lose G, Lalos O, Freeman RM, van Kerrebroeck P

American journal of obstetrics and gynecology1 Oct 2003Cited by 96 (Europe PMC)

PMID14586363DOI10.1067/s0002-9378(03)00593-3PepBankPUB-14586363

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with nocturia, 33 (46%) desmopressin patients versus 5 (7%) placebo patients achieved at least 50% fewer nocturnal voids (P<.0001).
In plain wordsIn women with nocturia, desmopressin produced at least 50% fewer nocturnal voids in 46%, compared with 7% with placebo.
Peptide
Desmopressin
Outcome
IncreaseAt least 50% reduction in nocturnal voids
Study
n = 144
Comparator
Placebo
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg, 0.2 mg, or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Responders
33 patients
desmopressin
Response rate
46%
desmopressin
Responders
5 patients
placebo
Response rate
7%
placebo
Source sentences
Summary
For desmopressin, 33 (46%) patients had a 50% or greater reduction in nocturnal voids against baseline levels compared with 5 (7%) patients receiving placebo (P<.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
Women aged 18 years or older with nocturia (>or=2 voids per night with a nocturia index score >1) received desmopressin (0.1 mg, 0.2 mg, or 0.4 mg) during a 3-week dose-titration period.
Summary · context
After a 1-week washout period, patients who responded in this period received desmopressin or placebo in a double-blind fashion for 3 weeks.
Summary · context
In double-blind phase, 144 patients were randomly assigned to groups (desmopressin, n=72; placebo, n=72).
Report a problemFND-1458636301
02HumanRandomized controlled trialEfficacy outcome
In women with nocturia, voiding, sleep duration, nocturnal diuresis, and urine-volume ratios changed significantly in favor of desmopressin versus placebo (P<.0001).
In plain wordsIn women with nocturia, voiding, sleep, urine production, and urine-volume ratios changed significantly in favor of desmopressin compared with placebo.
Peptide
Desmopressin
Outcome
Direction not reportedNocturnal voiding, sleep and urine-volume outcomes
Study
n = 144
Comparator
Placebo
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
0.1 mg, 0.2 mg, or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
P value
< 0.0001
desmopressin versus placebo
Source sentences
Summary
The mean number of nocturnal voids, duration of sleep until the first nocturnal void, nocturnal diuresis, and ratios of nocturnal per 24 hours and nocturnal per daytime urine volumes changed significantly in favor of desmopressin versus placebo (P<.0001).
3 context sentences(design, population, supporting numbers)
Summary · context
Women aged 18 years or older with nocturia (>or=2 voids per night with a nocturia index score >1) received desmopressin (0.1 mg, 0.2 mg, or 0.4 mg) during a 3-week dose-titration period.
Summary · context
After a 1-week washout period, patients who responded in this period received desmopressin or placebo in a double-blind fashion for 3 weeks.
Summary · context
In double-blind phase, 144 patients were randomly assigned to groups (desmopressin, n=72; placebo, n=72).
Report a problemFND-1458636302
03HumanNon-randomized trialSafety outcome
In women with nocturia, headache occurred in 22% during desmopressin dose titration.
In plain wordsIn women with nocturia, headache occurred in 22% during desmopressin dose titration.
Peptide
Desmopressin
Outcome
Not applicableHeadache during titration
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
0.1 mg, 0.2 mg, or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Headache
22%
dose titration
Source sentences
Summary
In the dose-titration phase headache (22%), nausea (8%), and hyponatremia (6%) were reported.
3 context sentences(design, population, supporting numbers)
Summary · context
Women aged 18 years or older with nocturia (>or=2 voids per night with a nocturia index score >1) received desmopressin (0.1 mg, 0.2 mg, or 0.4 mg) during a 3-week dose-titration period.
Summary · context
After a 1-week washout period, patients who responded in this period received desmopressin or placebo in a double-blind fashion for 3 weeks.
Summary · context
In double-blind phase, 144 patients were randomly assigned to groups (desmopressin, n=72; placebo, n=72).
Report a problemFND-1458636303
04HumanNon-randomized trialSafety outcome
In women with nocturia, nausea occurred in 8% during desmopressin dose titration.
In plain wordsIn women with nocturia, nausea occurred in 8% during desmopressin dose titration.
Peptide
Desmopressin
Outcome
Not applicableNausea during titration
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.1 mg, 0.2 mg, or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Nausea
8%
dose titration
Source sentences
Summary
In the dose-titration phase headache (22%), nausea (8%), and hyponatremia (6%) were reported.
3 context sentences(design, population, supporting numbers)
Summary · context
Women aged 18 years or older with nocturia (>or=2 voids per night with a nocturia index score >1) received desmopressin (0.1 mg, 0.2 mg, or 0.4 mg) during a 3-week dose-titration period.
Summary · context
After a 1-week washout period, patients who responded in this period received desmopressin or placebo in a double-blind fashion for 3 weeks.
Summary · context
In double-blind phase, 144 patients were randomly assigned to groups (desmopressin, n=72; placebo, n=72).
Report a problemFND-1458636304
05HumanNon-randomized trialSafety outcome
In women with nocturia, hyponatremia occurred in 6% during desmopressin dose titration.
In plain wordsIn women with nocturia, low blood sodium occurred in 6% during desmopressin dose titration.
Peptide
Desmopressin
Outcome
Not applicableHyponatremia during titration
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.1 mg, 0.2 mg, or 0.4 mg · oral · 3 weeksAs given in this study (human).
Measurements
Hyponatremia
6%
dose titration
Source sentences
Summary
In the dose-titration phase headache (22%), nausea (8%), and hyponatremia (6%) were reported.
3 context sentences(design, population, supporting numbers)
Summary · context
Women aged 18 years or older with nocturia (>or=2 voids per night with a nocturia index score >1) received desmopressin (0.1 mg, 0.2 mg, or 0.4 mg) during a 3-week dose-titration period.
Summary · context
After a 1-week washout period, patients who responded in this period received desmopressin or placebo in a double-blind fashion for 3 weeks.
Summary · context
In double-blind phase, 144 patients were randomly assigned to groups (desmopressin, n=72; placebo, n=72).
Report a problemFND-1458636305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.